<DOC>
	<DOCNO>NCT00104143</DOCNO>
	<brief_summary>This study compare effect A4I antagonist placebo MRI lesion , clinical endpoint , safety patient relapse Multiple Sclerosis ( MS ) . Eligible patient randomize receive placebo A4I antagonist , 20mg , 80mg 300mg , po bid . Patients undergo MRI brain scan MS clinical evaluation interval throughout study . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study A4I Antagonist Patients With Relapsing Multiple Sclerosis .</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>adult patient , 1859 year age ; relapse multiple sclerosis patient type 14 ( establish McDonald criterion ) ; &gt; =1 MS attack Gdenhancing MRI lesion 1 month 1 year enrollment ; EDSS score &lt; =6.5 ; inadequate response approve treatment ( Canada ) . MS attack within 1 month enrollment ; systemic corticosteroid within 1 month enrollment ; MS treatment ( nonsymptomatic ) within specify period enrollment ; infection require systemic antiinfective treatment vaccination live vaccine within 1 month enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>